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Aims. This study investigated the association of autoantibodies binding to oxidized low-density lipoproteins (oxLDL) in diabetic
retinopathy (DR). Methods. Plasma from 229 types 1 and 2 patients with DR including diabetic macular edema (DME) and
proliferative diabetic retinopathy (PDR) was analysed with ELISA-based assay to determine IgA, IgG, and IgM autoantibody levels
binding to oxLDL. The controls were 106 diabetic patients without retinopathy (NoDR) and 139 nondiabetic controls (C). Results.
PDR group had significantly higher IgA autoantibody levels than DME or NoDR: mean 94.9 (SD 54.7) for PDR, 75.5 (41.8) for
DME (𝑝 = 0.001), and 76.1 (48.2) for NoDR (𝑝 = 0.008). There were no differences in IgG, IgM, or IgA that would be specific
for DR or for DME. Type 2 diabetic patients had higher levels of IgA autoantibodies than type 1 diabetic patients (86.0 and 65.5,
resp., 𝑝 = 0.004) and the highest levels in IgA were found in type 2 diabetic patients with PDR (119.1, 𝑝 > 0.001). Conclusions. IgA
autoantibodies were increased in PDR, especially in type 2 diabetes. The high levels of IgA in PDR, and especially in type 2 PDR
patients, reflect the inflammatory process and enlighten the role of oxLDL and its autoantibodies in PDR.
1. Introduction
Diabetes and its long-term complications continue to rep-
resent a severe health problem all around the world. A
number of recent studies have emphasized that diabetes
carries a strong inflammatory component and the induction
of vascular inflammation in diabetes involves a dysregulation
of oxidation reaction [1–3]. Elevated plasma levels of circu-
lating oxidized low-density lipoprotein (oxLDL) have been
associated with obesity-related metabolic disturbances such
as the metabolic syndrome and diabetes [4]. The presence of
vascular oxidative stress and low-density lipoprotein (LDL)
with increased susceptibility to oxidation is especially promi-
nent in type 2 diabetes [5].
Oxidized low-density lipoproteins are immunogenic [6]
and circulating autoantibodies binding to oxidized epitopes
of oxLDL have been detected in human and animal plasma
[7, 8]. Inmousemodels of atherosclerosis immunoglobulinM
(IgM) type autoantibodies binding to oxLDL have exhibited
putative atheroprotective properties [9]. In some studies,
the concentrations of serum IgA binding to oxidized LDL
have been elevated in subjects with metabolic abnormalities
[8] and this phenomenon correlated with plasma levels
of inflammatory mediators [10]. Furthermore, plasma IgA
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autoantibody levels binding to oxLDL have been shown to
be positively and IgG autoantibody levels to be negatively
associated with markers of glucose metabolism and also to
be independent risk factors for type 2 diabetes [8].
The levels of autoantibodies binding to oxLDL decline
with age, diabetes duration, and glycated hemoglobin
(HbA1c) levels [1, 11]. This phenomenon has been attributed
to increased formation of oxLDL-specific immune complexes
[12]. It seems that these complexes [13] as well as the oxLDL
itself [14] can induce macrophages to be converted into foam
cells.The autoantibodies induce the macrophages to produce
cytokines [15] which in turn activate endothelial cells and
trigger an inflammation cascade [13, 16]. The presence of
inflammation and activation of endothelial cells are also key
elements in the initiation of diabetic retinopathy (DR) [17, 18].
Previously, oxLDL has been demonstrated to play a role in the
development of DR since immunostaining of apolipoprotein
B (apoB) oxLDL has been detected in the retinas of type
2 diabetic patients with or without DR and an increase in
oxLDL levels reflects the severity of retinopathy [19]. In
another study, Fu et al. demonstrated that the oxidative stress
was induced by modified LDL in DR; that is, the modified
LDL exerted toxic effects on the capillary pericytes [20].
Furthermore, high levels of oxLDL in immune complexes
have been shown to associate with progression of retinopathy
in type 1 diabetes [21].
Plasma levels of autoantibodies binding to oxLDL might
serve as a biomarker for the severity of the diabetic retinopa-
thy, but their role is not yet well characterized. The purpose
of this study was to investigate the levels of autoantibodies
binding to oxLDL in the plasma of diabetic patients with
and without diabetic retinopathy in a homogenous, well-
characterized Finnish study population.
2. Methods
2.1. Study Subjects. This is a case-control study with the
study population (Figure 1) consisting of 229 diabetic patients
with clinically moderate to severe DR (DR group) from
OuluUniversity Hospital or Helsinki University Hospital and
106 diabetic patients without signs of retinopathy (noDR
group) attending fundus imaging for screening of DR inOulu
City Health Centers. The diabetic patients were matched
for duration of diabetes by including only those patients
with a disease duration of at least 10 years in the noDR
group since diabetes’ duration and hyperglycemia are the
main prognostic factors for the development of DR. The
diagnosis and classification of DR were made in the clinical
examination and/or from fundus images by experienced
ophthalmologist at the Department of Ophthalmology of
Oulu and Helsinki University Hospital [22, 23]. We also
examined 139 nondiabetic patients undergoing eye surgery in
the Helsinki University Hospital as control group (C group).
The DR patients were divided into two groups accord-
ing to their retinopathy status (Figure 1). Thus the DME
group consisted of 65 patients with clinically significant
diabetic macular edema (DME) and the proliferative dia-
betic retinopathy (PDR) group consisted of 76 patients.


















Figure 1: Study population.
Health Centers filled in a questionnaire and provided blood
samples. The questionnaire included questions about their
diabetes, diabetic complications, other diseases and medi-
cations, and lifestyle. Subjects from the Helsinki University
Hospital also provided blood samples and filled in a different
type of questionnaire, but therefore some data is missing
from the tables and figures. Diabetic patients who had been
previously diagnosed with microalbuminuria or proteinuria
were classified as having nephropathy and the diagnosis of
neuropathy was based on a previous diagnosis according to
the questionnaire. This study follows the guiding principles
of the Declaration of Helsinki and was approved by the Ethics
Committee of the Oulu University Hospital.
2.2. Laboratory Measurements. Plasma samples were taken
after an overnight fast, centrifuged, and stored −70∘C.
The levels of fasting plasma glucose, HbA1c, creatinine,
total cholesterol, LDL, high-density lipoprotein (HDL), and
triglycerides were determined from the blood samples pro-
vided by the subjects from Oulu University Hospital and
Oulu City Health Centers as routine laboratory measure-
ments in Oulu University Hospital. LDL was extracted from
a human plasma sample pool of seven healthy control
study subjects of both genders and purified with dialy-
sis [24]. Purified LDL was oxidized for 25min at +37∘C
with 0.5M malondialdehyde (MDA) [6]. The MDA-solution
used was produced from the MDA-base solution incu-
bated with 4N hydrochloric acid in +37∘C for 12–15 min-
utes until turning yellow and neutralized with 1N sodium
hydroxide.
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2.3. Autoantibody Measurements. Plasma IgG, IgM, and IgA
class autoantibody titers to oxidized LDL were measured
with chemiluminescence ELISA as previously described [25].
The measurement plates were coated with MDA-oxLDL and
incubated overnight at +4∘C. The wells were washed with
a buffer solution (phosphate buffered saline with ethylene-
diaminetetraacetic acid (PBS-EDTA)) and postcoated with
0.5% FISH-gelatin for one hour at room temperature. After
a second wash with PBS-EDTA, samples in 0.5% FISH-
gelatin were added and incubated overnight at +4∘C. Each
plate contained also a triplicate standards of commercial
purified immunoglobulins as controls (Sigma Aldrich, St.
Louis, MO), a zero-sample of pure PBS-EDTA-FISH-gelatin,
and two triplicate control samples (“high” and “low”), diluted
to cover as wide a range of the standard as possible. After a
third wash, the anti-human antibodies in 0.5% FISH-gelatin
were added and incubated for one hour at room temperature.
Subsequently the plates were washed with PBS-EDTA and
distilled water and then they were incubated with 0.33%
LUMIPHOS (Lumigen Inc. Southfield, MI) for 90 minutes
and analysed in a VICTORmultilabel counter (PerkinElmer,
Waltham, MA).
In order to maintain the sample luminescence counts
within the standard range, the samples were diluted in FISH-
gelatin. Prior to the final analysis, we performed multiple
tests to determine the dilutions for each autoantibody type.
The selection of the dilutions was based on the lowest
coefficient of variation (CV) between measurements. The
dilutions were 1 : 2000 for IgG, 1 : 1333 for IgM, and 1 : 400
(MDA-ox) or 1 : 100 (Cu-ox) for IgA.We performed triplicate
measurements of each sample. The CV was calculated from
each triplicate measurement. The CVs were below 20% in all
samples.
An average relative light unit (RLU) value was calcu-
lated from the luminescence counts by reducing the blank
value (zero-sample) from the average luminescence count
of the triplicate measurements. A linear standard curve
was created and the RLUs were converted into relative
plasma autoantibody levels by dividing the RLUs with the
standard curve slope and then multiplied by the dilu-
tion coefficient. The levels are expressed as relative units
(RU).
2.4. Statistical Analyses. Statistical analysis was performed
with the IBM SPSS software (IBM Corporation, Armonk,
NY). The statistical significance of the autoantibody lev-
els between two study groups was calculated with inde-
pendent samples 𝑡-test and ANOVA was used for com-
parisons between several study groups. Crosstabs (Chi-
square) was used to assess differences between categorical
variables. Multiple linear regression analysis was used to
explain the levels of autoantibodies and variables included
in the model were selected due to correlation (Pear-
son correlation) with autoantibody levels (sex, age, BMI,
diabetes duration and type, gHbA1c, LDL, and medica-
tions). 𝑝 values less than 0.05 were considered statistically
significant.
Table 1: Clinical characteristics and levels of MDA-ox LDL of dia-
betic patients with diabetic retinopathy (DR) and without diabetic
retinopathy (noDR). The data are expressed as mean (standard
deviation (SD)) or 𝑛 (percent (%)).
DR NoDR
𝑝
𝑛 = 229 𝑛 = 106
Age (years) 58.9 (14.4) 55.9 (16.3) 0.126
Gender 0.411
Women 97 (42.4%) 50 (47.2%)
Men 132 (57.6%) 56 (52.8%)
BMI (kg/m2) 28.8 (5.8) 27.2 (5.0) 0.056
Diabetes 0.636
Type 1 98 (43.8%) 50 (47.2%)
Type 2 126 (56.2%) 56 (52.8%)
Duration 22 (11.5) 24.2 (7.8) 0.046
BP systolic (mmHg) 152.2 (23.6) 133.9 (13.5) 0.032
BP diastolic (mmHg) 83.8 (11.8) 83.6 (10.1) 0.976
Nephropathy 64 (37.2%) 16 (15.8%) <0.001
Neuropathy 68 (40.5%) 19 (18.4%) <0.001
Hypertension 171 (76.7%) 55 (51.9%) <0.001
Cholesterol (mMol) 4.1 (1.1) 4.1 (0.9) 0.553
LDL (mMol) 2.3 (0.9) 2.1 (0.8) 0.122
HDL (mMol) 0.9 (0.5) 1.1 (0.5) <0.001
Triglycerides (mMol) 1.2 (1.4) 0.6 (0.8) <0.001
Creatinine (𝜇Mol) 102 (82.8) 72.9 (21.8) <0.001
Glucose (mMol) 8.9 (4.0) 8.0 (2.9) 0.029
HbA1c (%) 8.5 (1.8) 7.7 (1.3) <0.001
MDA-ox IgG 6827 (5397) 7177 (5056) 0.579
MDA-ox IgM 3316 (4489) 3536 (2933) 0.644
MDA-ox IgA 81.3 (45.4) 76.1 (48.2) 0.346
BMI: body mass index, BP: blood pressure, HbA1c: glycated hemoglobin,
HDL: high-density lipoprotein, and LDL: low-density lipoprotein.
3. Results
3.1. Baseline Characteristics. Theclinical characteristics of the
study groups are shown in Tables 1 and 2. The DR (𝑛 = 229)
and NoDR (𝑛 = 106) groups did not differ significantly in
terms of age, sex, body mass index (BMI), diabetes type or
LDL, and total cholesterol concentrations, but the DR group
had worse diabetes control (Table 1) than the NoDR group,
with the mean value of glycated hemoglobin being higher in
the DR group. The DR group had poorer lipid profile having
higher triglyceride and lower HDL concentration than the
NoDR group (Table 1).
The mean age of the patients in the DME group was
older than in the PDR group (63.6 and 55.4 years, resp., 𝑝 <
0.001) (Table 2). As expected, the proportion of patients with
type 2 diabetes was higher in the DME group than in the
PDR group (72.3% and 39.5% of patients in DME and PDR,
respectively (𝑝 < 0.001)) but there was some overlapping.
There were no differences in other measured clinical char-
acteristics between the groups (Table 2), except that more
patients suffered from nephropathy (microalbuminuria) in
the PDR group as compared to the DME group (42.9% versus
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Table 2: Clinical characteristics of the diabetic retinopathy patients
(DR) with diabetic macular edema (DME) or proliferative retinopa-
thy (PDR).Thedata are expressed asmean (standard deviation (SD))
or 𝑛 (percent (%)).
DME PDR
𝑝
𝑛 = 65 𝑛 = 76
Age (years) 63.6 (10.2) 55.4 (15.1) <0.001
Gender 0.272
Women 29 (44.6%) 27 (35.5%)
Men 36 (55.4%) 49 (64.5%)
BMI (kg/m2) 30.1 (5.8) 28.2 (5.6) 0.057
Diabetes <0.001
Type 1 18 (27.7%) 46 (60.59%)
Type 2 47 (72.3%) 30 (39.5%)
Duration 22.1 (9.5) 24.9 (10.2) 0.095
BP systolic (mmHg) 145.4 (24.1) 152.2 (20.6) 0.448
BP diastolic (mmHg) 78.3 (7.1) 83.9 (13.9) 0.305
Nephropathy 15 (23.8%) 30 (42.9%) 0.020
Neuropathy 21 (33.9%) 32 (46.4%) 0.145
Hypertension 54 (84.4%) 55 (78.6%) 0.389
Cholesterol (mMol) 4.6 (1.1) 4.7 (1.1) 0.496
LDL (mMol) 2.7 (0.9) 2.8 (0.9) 0.737
HDL (mMol) 1.3 (0.3) 1.3 (0.4) 0.966
Triglycerides (mMol) 1.5 (1.0) 2.0 (1.7) 0.086
Creatinine (𝜇Mol) 91.6 (64.2) 114.0 (103.7) 0.124
Glucose (mMol) 8.9 (3.9) 9.3 (3.9) 0.521
HbA1c (%) 9.2 (2.1) 9.1 (1.7) 0.657
BMI: body mass index, BP: blood pressure, HbA1c: glycated hemoglobin,
HDL: high-density lipoprotein, and LDL: low-density lipoprotein.
Table 3: Percentages of diabetic patients using lipid lowering,
antihypertensive, oral diabetes medication, insulin, or ASA.
Yes No Missing
𝑁 % 𝑁 % 𝑁 %
ACE/ATII 164 49.0 151 45.1 20 6.0
𝛽-Blocker 113 33.7 210 62.7 12 3.6
ASA 104 31.0 219 65.4 12 3.6
Statin 109 32.5 210 62.7 16 4.8
Oral DMmedication 121 36.1 205 61.2 9 2.7
Insulin 215 64.2 55 16.4 65 19.4
23.8%, 𝑝 = 0.020). The medications the diabetic subjects
used are shown in Table 3. The diabetic patients, according
to clinical guidelines, had medications influencing blood
pressure and lipid profile in addition to antidiabetic drugs and
the percentage of patients having beta blocker, ACE inhibitor,
and statinmedicationswas higher inDR group than inNoDR
group. No differences in insulin, oral diabetes medication, or
ASA were found between DR and NoDR.
3.2. Autoantibody Levels in DR. Retinopathy did not influ-
ence the measured autoantibody levels: IgG, IgM, or IgA;
autoantibody levels did not differ significantly between the
DR and noDR groups (𝑝 = 0.644, 𝑝 = 0.579, and 𝑝 =
0.346, resp.) (Table 1, Figure 2). However, PDR group had
significantly increased IgA autoantibody levels; that is, the
mean value of IgA was 94.9 (SD 54.7) compared with 75.5
(SD 41.8) in DME (𝑝 = 0.023) (Figure 2) and 76.1 (SD 48.2,
𝑝 = 0.008) in NoDR (Table 1).
3.3. Autoantibody Levels in Diabetes. We also wanted to
assess the effect of diabetes on autoantibody levels. Diabetes
influenced IgM autoantibody levels: diabetic patients (both
DR and NoDR) had significantly lower IgM autoantibody
levels against MDA-oxLDL than nondiabetic controls (3389
(SD 3998) versus 4258 (SD 3578), 𝑝 = 0.043), but the IgG and
IgA autoantibody levels did not differ significantly between
the D group (DR and NoDR) and the C group. The levels for
for IgM, IgG, and IgA were 3389 (SD 3998), 6944 (SD 5280),
and 79.6 (SD 46.3) for D group and 4258 (SD 3578), 6874 (SD
4718), and 80.7 (SD 46.2) for C group, respectively.
3.4. Effect of Diabetes Type on Autoantibody Levels. Themean
age of type 1 diabetic patients was 45.7 years (SD 13.5) and
of type 2 diabetic patients was 66.8 (SD 9.6). We subdivided
them according to type of diabetes, and it was found that
the IgA autoantibody levels were significantly lower in type 1
diabetes than in type 2 diabetes (65.5 (SD 30.5) for type 1 and
86.0 (SD 51.3) for type 2, 𝑝 < 0.001) (Figure 2). We further
tested the effect of diabetes type in PDR group and found that
the IgA levels were highest in the PDR group having type 2
diabetes (119.1 (SD 64.1) versus 77.5 (SD 38.7) in PDR type 1
population (𝑝 = 0.002)) (Figure 3).
3.5. Multiple Linear Regression. Multiple linear regression
was run to test the main determinants of autoantibody levels.
Variables in the model were sex, age, BMI, diabetes duration
and type, gHbA1c, LDL, and medications. The variables that
added statistically significantly to the equation are shown in
Table 4. In general, IgG autoantibodies were increased by
type 2 diabetes and decreased by oral diabetes medication
and statin medication (𝑅2 = 0.122). High LDL concentration
influenced IgM levels and they were decreased by female sex
and oral diabetes medication (𝑅2 = 0.161). Furthermore, it
was found that IgA autoantibody levels were increased by
increasing age, gHbA1c, LDL, and ASA medication (𝑅2 =
0.227).
4. Discussion
In this study, we have investigated the autoantibody levels
against MDA-OxLDL in diabetic retinopathy, an observa-
tional analysis using a cross-sectional study design, and found
that the levels of IgA type autoantibodies were increased in
PDR patients as compared with DME or noDR and the type
2 patients in PDR group had the highest levels.
There is evidence that autoantibodies binding to oxLDL
are involved in the pathogenesis of DR and it may be that
its tissue-specific function is related to immune complexes.
It has been shown by Wu et al. that oxidized LDL measured
as intraretinal immunofluorescence of apoB-100 (the protein
component of LDL) is present in human donor diabetic
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Figure 2: Autoantibody levels against MDA-oxLDL (MDA-Ox IgG, MDA-Ox IgM, and MDA-Ox IgA) in macular edema patients (DME),























Figure 3: IgA autoantibody levels against MDA-oxLDL (MDA-Ox
IgA) inmacular edemapatients (DME) andproliferative retinopathy
(PDR) patients divided by diabetes types (type 1 and type 2). The
levels are expressed as mean relative units and standard deviation.
retinas and the level of immunofluorescence increases with
the severity of DR [19]. Even at the earliest stages of DR before
the onset of clinical retinopathy, an aggregation of oxidized
LDL has been detected in the retina.The oxidized LDL is also
an effective trigger of apoptosis in retinal capillary pericytes
leading to the breakdown of the blood-retina barrier, a key
event in the development of DR [26]. Extravasated modified
lipoproteins may play a key role in the development of
DR; the phenomenon is described in human, animal, and
cell culture studies [20] indicating that lipoproteins may be
potential causal factors in the development of DR and that
the pathogenic process occurring in DR might be somewhat
parallel to that observed in atherosclerosis. Furthermore,
OxLDL may either be important in the pathogenesis of DR
per se or act as a trigger for inflammation in the retina and
in the surrounding retinal vessels. It has been shown that
modified lipoproteins activate innate and adaptive immune
responses with proinflammatory signals and disturb the
integrity of the microvasculature [27]. Also the study of
Fu et al. supports this hypothesis, since oxLDL-immune
complexes triggered apoptosis and enhanced inflammatory
cytokine secretion towards retinal pericytes [28]. Further-
more, it seems that oxLDL and autoantibodies might also be
important in prognosis of DR as oxLDL-immune complexes
and advanced glycation end products modified low-density
lipoproteins (AGE-LDL) were associated with an increased
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Table 4: Multiple linear regression for autoantibody levels. The
variables included in the model were sex, age, BMI, diabetes
duration and type, gHbA1c, LDL, and medications. Negative values
indicate inverse effect and for sex, female sex has decreasing effect.
Variable 𝐵 95% confidenceinterval 𝑝
MDAOx-IgG
Constant 5070.0 0.005
Oral diabetes medication −3857.0 −5693.9 to −2020.1 <0.001
Diabetes type 3624.4 1590.1 to 5658.0 0.001
Statin medication −1954.9 −3495.4 to −414.3 0.013
MDAOx-IgM
Constant −1777.7 <0.001
Sex −995.8 −1912.8 to −78.69 0.033
LDL 919.5 314.5 to 1524.4 0.003
Oral diabetes medication −2038.5 −3415.0 to −662.0 0.004
MDAOx-IgA
Constant −40.93 <0.001
Age 0.84 0.37 to 1.32 0.001
gHbA1c 3.64 0.44 to 6.87 0.026
ASA 21.91 8.20 to 35.62 0.003
LDL 8.08 0.91 to 15.25 0.027
risk of progression to advanced retinopathy in patients with
type 1 diabetes [21].
As stated, there seem to be several similarities in the
role of oxLDL in the pathogenesis of DR and atherosclerosis.
There is evidence in humans that the IgM antibodies binding
to oxLDL might have an atheroprotective effect as shown in
human and mouse studies [9, 24], although with controversy
[29]. It seems that instead of being an independent risk factor
in atherosclerosis, IgM autoantibodies maymodulate the risk
of coronary artery disease associated with elevated levels of
oxidative biomarkers [30]. The role of IgA autoantibodies
binding to oxLDL in atherosclerosis still remains somewhat
unclear. It has been postulated that high autoantibody levels
binding to oxLDL could well be useful clinical parameters of
lipoprotein oxidation for detecting the presence of macrovas-
cular disease in diabetic patients [31]. Our results suggest
that determining plasma autoantibody levels against oxLDL
might represent a potential indicator for diabetic retinopathy,
but this deserves further studies.
Plasma levels of autoantibodies against oxLDL have also
been shown to correlate with diabetes or diabetes risk.
Previously, low levels of oxLDL antibodies, especially of the
IgG type autoantibodies, have been associated with type 2
diabetes, since a low total oxLDL autoantibody level has been
linkedwith the development of type 2 diabetes in women [32]
and inversely correlatingwithmarkers of glucosemetabolism
[8]. Furthermore, a harmful role has been proposed for
IgA autoantibodies, since higher levels of IgA autoantibodies
increased the risk of diabetes in a population-based cohort
although no association was found between the levels of
IgM autoantibodies and glucose metabolism in a previous
study [8]. We found that the IgA levels were highest in type
2 diabetes among PDR group, indicating that the higher
levels found were not only disease-specific but also diabetes-
type-specific. Previously, it has been shown that these IgA
autoantibodies were associated with inflammatory markers,
obesity, and type 2 diabetes [10]. In PDR the inflammation
and oxidative processes are more active than in DME and
it seems that, in type 2 diabetes with PDR, these processes
might be further increased as a consequence to local (or
general) oxidative stress. It seems that IgA autoantibodies to
oxLDL might have a role in the complications encountered
in type 2 diabetes, at least at the microvascular level. Other
types of autoantibodies seem to be associatedwith other types
of diabetes complications, since IgG type autoantibody was
increased in type 1 diabetes [33] and may have a pathogenic
role in the development of nephropathy [34].
In our case-control study, we observed a significant
increase in levels of IgA autoantibodies in PDR as compared
to NoDR or DME groups and this increase was most
prominent in type 2 PDR patients. This is the first analysis of
autoantibody levels binding to oxLDL in patients with type
2 diabetes and retinopathy. In the present study, a relatively
large number of well-characterized patients including both
type 1 and type 2 diabetic patients with both DME and PDR
were studied.Nonetheless, since diabetes control, retinopathy
screening and treatment of DR are stringently regulated in
Finland, the study population is rather homogenic. Some
limitation of the current study might be that the levels
of free autoantibodies and the autoantibodies bound to
oxLDL forming immunocomplexes [10] may vary between
individuals. Our method will not measure total autoantibody
levels to or reflect the total immune response to the antigen.
This is a universal phenomenon in measuring the circulating
antibodies in plasma samples. In addition, the plasma levels
of oxLDL autoantibodies are not specific for retinal damage
might also be influenced by the severity of atherosclerosis
and/or renal disease or might be affected by influence of
diabetes on the vascular wall [35]. There is also some
contrasting evidence about using anti-oxLDL as a marker, as
antibody concentrations might reflect individual immunity
strength, which remains to be solved in future studies.
5. Conclusions
Our study shows that the plasma levels of IgA type autoan-
tibodies were increased in PDR and especially the type 2
patients in PDR group had the highest levels. Our results
highlight the role of oxLDL and its autoantibodies in PDRand
suggest that they might have relevance as an indicator of DR.
Our understanding of oxLDL in the pathogenesis of diabetic
retinopathy is increasing but there are still unexplored areas.
Clarifying the role of inflammation and immunity in the
development of diabetic vascular complications deserves
increased attention and may bring tools for DR prevention
and treatment.
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